Aptinyx (NASDAQ:APTX) Releases Earnings Results, Beats Expectations By $0.02 EPS

Aptinyx (NASDAQ:APTX – Get Rating) announced its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02, Fidelity Earnings reports. During the same quarter last year, the business posted ($0.22) EPS.

APTX opened at $0.70 on Friday. Aptinyx has a 52-week low of $0.57 and a 52-week high of $4.73. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average of $1.78 and a 200-day moving average of $2.43.

A number of equities analysts have weighed in on APTX shares. Zacks Investment Research cut Aptinyx from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Truist Financial decreased their price objective on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday, April 8th. BMO Capital Markets cut their target price on shares of Aptinyx from $12.00 to $6.00 in a research note on Friday, April 8th. Cantor Fitzgerald lowered their price objective on Aptinyx from $11.00 to $5.00 and set an “overweight” rating for the company in a report on Friday, April 8th. Finally, SVB Leerink cut their price objective on Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, April 21st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Aptinyx currently has a consensus rating of “Buy” and an average target price of $3.88.

A number of hedge funds and other institutional investors have recently bought and sold shares of APTX. Vanguard Group Inc. grew its position in Aptinyx by 8.4% during the first quarter. Vanguard Group Inc. now owns 1,964,058 shares of the company’s stock worth $4,459,000 after buying an additional 152,943 shares in the last quarter. BlackRock Inc. increased its position in shares of Aptinyx by 1.5% during the fourth quarter. BlackRock Inc. now owns 1,374,768 shares of the company’s stock valued at $3,669,000 after purchasing an additional 20,928 shares during the period. Millennium Management LLC raised its stake in shares of Aptinyx by 19.7% in the fourth quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock valued at $3,329,000 after purchasing an additional 205,553 shares in the last quarter. Susquehanna International Group LLP lifted its position in Aptinyx by 56.8% in the fourth quarter. Susquehanna International Group LLP now owns 243,275 shares of the company’s stock worth $650,000 after purchasing an additional 88,141 shares during the period. Finally, Northern Trust Corp boosted its stake in Aptinyx by 203.7% during the first quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock worth $498,000 after buying an additional 147,357 shares in the last quarter. Institutional investors own 55.97% of the company’s stock.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Further Reading